Collegium Pharmaceutical Inc (COLL)

[floblu14]

IMHO - I wouldn't be surprised if TAKEDA bought out COLL.

Rationale:

COLL - is way too cheap! At 7 times earnings plus a $100M buyback - the stock has been going NO-WHERE. If this was a biotech - the stock would be $100+ PPS due to earnings alone.

Most importantly - Colleen Tupper - Prior to joining Collegium [in May 2021], Colleen most recently served as Chief Financial Officer, U.S. Business Unit as well as a member of the U.S. Business Unit Executive Leadership Team and the Global Finance Leadership Team at Takeda.

Prior to that role, Colleen held several roles of increasing responsibility at Shire Pharmaceuticals (acquired by Takeda in 2019) including Vice President, U.S. Commercial Finance, Vice President, Finance Integration Lead, and Vice President, Head of Finance Global Neuroscience and Ophthalmics.

https://www.collegiumpharma.com/people/colleen-tupper/
______________________________________

On April 19, 2018 Takeda made an official bid of about $66.22 (U.S.) per share, which had a value of about $60 billion (U.S.). ... Under the final bid, Shire agreed to be acquired for about $62.2 billion (U.S.), or $66.22 per share, made up of $30.33 per share in cash and 0.839 shares of Takeda stock. Jan 8, 2019